Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Citi reiterates 'sell' rating on BT Group

Thu 08 Jan 2026 10:45

(Sharecast News) - Citi reiterated its 'sell' rating and 140p price target on BT Group on Thursday as it said consumer downgrades should be in focus, not just Openreach line loss. The main metric that investors will likely focus on at the third-quarter results on 5 February will again be Openreach broadband line losses, the bank said.

"As 51% of Openreach revenue is internal, this metric, and Openreach financials, can be supported by BT's downstream divisions, albeit at a cost to them if non-value adding volumes are being pursued," it said.

"While Openreach financials have positively surprised us in recent periods by continuing to grow, Consumer has seen persistent downgrades, accounting for £105m of the group's £131m 2026/27 EBITDA consensus downgrade over the last 12 months, with future EBITDA growth expectations also compressing."

At 1040 GMT, the shares were down 1% at 180.20p.

Share this article

Related Sharecast Articles

Thu 16 Jul 2026 14:42
RBC Capital Markets keeps Ashtead at 'outperform'
(Sharecast News) - RBC Capital Markets said first‑half trading at Ashtead Technology was solid, but slightly softer margins linked to ongoing Middle East and Asia disruptions prompted the broker to trim its estimates.
Thu 16 Jul 2026 14:30
St James's Place tumbles as two more appointed representatives leave
(Sharecast News) - St James's Place tumbled on Thursday following a report that two more of its large appointed representatives have left the network.
Thu 16 Jul 2026 14:17
Oxford Biomedica inks service deal with Plowshare Therapies
(Sharecast News) - Oxford Biomedica announced on Thursday that it has signed an agreement to provide process development and AAV GMP manufacturing services to Plowshare Therapies, supporting the biotechnology company's gene therapy programme for rare genetic diseases.
Thu 16 Jul 2026 12:21
Berenberg lowers target price on Rio Tinto following Q2 update
(Sharecast News) - Analysts at Berenberg cut their price target on Rio Tinto from 8,200p to 8,100p on Thursday, saying higher‑than‑expected diesel costs in the Pilbara were likely to keep unit‑cost pressure elevated, while parts of the miner's Q2 production update pointed to downside risks in iron ore.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Policies and important information
 

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statement | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Staying secure | Statutory and Regulatory disclosures | Whistleblowing programme

 

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026